This is where artificial intelligence is starting to make a real difference. Instead of relying solely on what doctors can observe in the clinic, AI tools can analyze patterns across brain scans, genetic data, movement sensors, and more—giving clinicians a clearer, earlier picture of what’s happening.
The goal isn’t to replace doctors, but to give them better tools. Tools that can support earlier diagnosis, more tailored treatment plans, and smarter clinical trials.
Download your free PDF copy now to learn more!
How AI is Changing Parkinson’s Treatment
After Alzheimer’s, Parkinson’s is the most common neurodegenerative disorder—and it becomes more likely with age. It starts in the brain’s substantia nigra, where dopamine-producing neurons gradually die off. That loss leads to the familiar motor symptoms: tremors, stiffness, slowed movement, balance issues. But the impact goes well beyond movement. Many people also experience depression, cognitive changes, and disruptions in things like digestion, blood pressure, and sleep.1
Right now, Parkinson’s is diagnosed mainly through clinical observation. Doctors look for key motor symptoms and evaluate how patients respond to dopamine-replacing drugs. But there are a few big issues with that approach:
- Diagnosis usually comes late—after 50–70 % of those dopamine neurons are already gone
- Assessments are subjective and vary between clinicians
- It’s hard to tell Parkinson’s apart from other similar disorders early on
This makes early intervention difficult, even though we know it can improve long-term outcomes.
This is exactly the kind of pattern-recognition challenge where AI and machine learning excels. These technologies are especially good at recognizing subtle patterns in complex data (patterns that are nearly impossible to catch with the naked eye). With the right training data, AI can help identify Parkinson’s earlier and track how it progresses more accurately over time.
On the treatment side, levodopa is still the go-to for managing motor symptoms, but it doesn’t work the same for everyone. ML algorithms like random forests and support vector machines are being used to predict individual responses to different medications, flag early signs of complications like levodopa-induced dyskinesia, and help fine-tune add-on therapies like dopamine agonists and MAO-B inhibitors.1,2
More advanced models, like convolutional neural networks, are also being applied to neuroimaging and multi-omics data. This allows researchers to group patients based on their symptoms, biology, or expected disease path, which is incredibly valuable when considering treatments like deep brain stimulation (DBS) or focused ultrasound (FUS).
What's even more exciting is the prospect of AI-powered wearable sensors. When combined with deep learning and time-series analysis, they can support “closed-loop” systems—treatments that adapt in real time based on a person’s changing symptoms or physiological signals.2
Clinical Trials
Clinical trials are essential for testing new treatments and technologies in Parkinson’s disease, but finding the right participants can be one of the biggest roadblocks. Especially for trials involving neurosurgical options like deep brain stimulation (DBS), selecting patients who are most likely to benefit is critical. It’s not just about safety—it’s about giving each intervention the best possible chance to succeed.
Traditionally, patient screening has relied on clinical judgment. Doctors look at symptoms, disease stage, and general health. But these assessments take time, vary from one clinician to another, and can miss the nuances that really matter for trial eligibility.
AI is starting to change that. Machine learning models can now pull from a wide range of data, such as medical records, imaging, genetics, biomarkers, and spot patterns that predict how someone might respond to a particular treatment.²
This means trials can:
- Identify the most appropriate participants more quickly
- Reduce the risk of enrolling patients who are unlikely to benefit
- Improve consistency across trial sites
- Even adjust eligibility in real time as new data becomes available
For example, AI can analyze fMRI and PET scans to pinpoint the areas of the brain most affected by PD, helping researchers match patients to the right neurosurgical intervention. It can also track things like cognitive changes or mood disorders—non-motor symptoms that often go overlooked but are important for trial outcomes. In some studies, AI has even been used to predict who’s likely to respond well to DBS, helping researchers design more targeted and effective studies from the start.2
And beyond neurosurgery, AI is helping expand trial inclusion by accounting for the full spectrum of PD symptoms, not just the obvious motor signs. That opens the door to more diverse participant groups and ultimately leads to treatments that work better for more people.
That said, challenges still exist—like ensuring data privacy, validating AI models across populations, and setting industry-wide standards. Making AI work safely and ethically in clinical trials will require close collaboration between researchers, regulators, and technology developers.
Smarter Scans, Better Decisions
Interpreting brain scans is both an art and a science—and in Parkinson’s disease, it’s often a challenge. Many neurodegenerative disorders look similar on imaging, and small structural changes can be hard to spot even for experienced radiologists. This is where AI is proving to be a powerful ally.
Using MRI data, AI tools can now help differentiate between Parkinson’s disease and similar conditions like essential tremor, something that can be tricky to do with symptoms alone. In one example, AI-based volumetric analysis highlighted differences in brain regions such as the occipital lobes, hippocampus, putamen, and mesencephalon. Patients with essential tremor, for instance, showed reduced volumes in the caudate nucleus and thalamus.2
This kind of detailed comparison can directly guide treatment decisions. For example, understanding whether someone has tremor-dominant PD versus another type of movement disorder helps determine whether they’re a candidate for neurosurgical interventions like DBS.
AI is also being used to predict how well someone might respond to DBS by analyzing brain activity patterns in fMRI scans. Models using machine learning techniques like logistic regression and K-nearest neighbors can look at whole-brain radiomic data and estimate treatment success before surgery even happens.2
On top of that, AI tools are improving how we interpret metabolic brain scans. By analyzing patterns of glucose use in different brain regions, these tools can distinguish PD from other Parkinsonian syndromes with impressive accuracy. In fact, a meta-analysis of 24 studies found AI’s diagnostic performance to be on par with that of specialist radiologists.2
What is important to remember is that AI isn’t replacing experts—it’s helping them see more, see earlier, and make decisions with greater confidence. This imaging insight feeds directly into how we plan and personalize interventions like DBS.
Personalizing DBS, Before and After Surgery
Accurate imaging is just one part of the equation—once a patient is identified as a candidate for DBS, the real challenge begins: finding the right stimulation settings. Traditionally, this has involved a lot of trial and error in outpatient visits, which can be time-consuming, inconsistent, and frustrating for both patients and clinicians.
More and more, AI is starting to take some of the guesswork out of that process.
New AI-powered systems can analyze brain imaging data to help predict the most effective DBS parameters for each patient—before treatment even begins. In one study, AI models trained on fMRI data were able to predict optimal stimulation settings with 88 % accuracy.3 That kind of precision could mean fewer clinic visits, faster symptom relief, and better long-term outcomes.
The FDA has already approved a handful of AI-assisted DBS systems, and they’re starting to make their way into clinical settings. These tools use deep learning not just to improve decision-making, but also to enhance the quality of the imaging itself—through noise reduction, artifact correction, and better segmentation of brain structures.2
Improved imaging clarity leads to more accurate targeting during surgery and makes it easier to monitor changes in motor and cognitive function over time. In some cases, AI has even helped visualize the subtle neuropsychiatric effects of DBS, something that’s hard to track manually.
Long-term, the goal is dynamic, adaptive stimulation. Think of it like a smart thermostat, but for your brain—adjusting stimulation levels in real time based on how a patient is doing, rather than relying on fixed settings. AI is laying the groundwork for that kind of closed-loop system.
In short, DBS is becoming more personalized, more responsive, and more efficient, with AI quietly powering much of that progress behind the scenes.
What Movement Can Tell Us—If AI is Paying Attention
One of the most visible signs of Parkinson’s is how it affects the way people move—especially how they walk. Shuffling steps, freezing, and reduced arm swing are common, and they can show up early in the disease, sometimes even before a diagnosis is made.
The challenge is that these changes can be subtle at first. In a short clinic visit, it’s easy to miss the full picture. But AI tools, especially those paired with wearable sensors, are starting to fill in the gaps.
Devices like accelerometers and gyroscopes can collect movement data continuously—not just during appointments, but throughout daily life. With machine learning, that data can be analyzed to spot patterns that may indicate early-stage Parkinson’s, or changes in symptoms over time. Some models are already reaching over 90 % sensitivity and specificity in detecting early signs.1
This kind of real-world monitoring gives doctors a clearer view of how someone is actually doing, not just on the day of the visit, but in between. It can help guide treatment decisions, flag when medications might need adjusting, or simply confirm that things are stable.
And for patients, it means less guesswork. They don’t have to rely only on how they’re feeling or what they remember reporting; they’ve got data backing them up. But understanding symptoms is only part of the equation. Managing treatment is the real day-to-day challenge.
Treatment Optimization
While diagnosis and monitoring are critical, the day-to-day challenge for most people with Parkinson’s is managing treatment, and it’s rarely straightforward. Medications like levodopa remain central to care, but responses vary widely between patients. Adjusting dosages, adding medications, and managing side effects often becomes a long-term balancing act.
AI is helping clinicians move beyond trial and error toward more precise, personalized care. Machine learning algorithms can process complex clinical data, including symptom patterns, medication history, side effects, and even movement data from wearables, to predict how a patient is likely to respond to a given therapy.1,4 This makes it possible to tailor treatment plans more effectively, reducing unnecessary adjustments and improving symptom control.
Some of these tools are being embedded directly into electronic health record systems. They don’t replace clinical judgment, but they offer something it often lacks: real-time analysis of patient-specific data, delivered at the point of care.
Beyond medication, AI is making neuromodulation smarter. Deep reinforcement learning is being tested to fine-tune DBS settings based on feedback over time. The goal isn’t just symptom control—it’s better outcomes with fewer side effects, like the speech or mood issues that can come with overstimulation.
The value of AI extends into day-to-day care as well. Virtual reality and robotic systems are being used to personalize rehabilitation, helping patients improve mobility, balance, and function in a way that adapts to their individual needs.
And across the broader care team, AI-powered coordination platforms are helping reduce the friction of managing a complex disease. By scanning clinical notes, schedules, and structured data, they can flag gaps in care, recommend follow-ups, and keep multidisciplinary teams aligned.
Conclusion
As AI continues to find its place in Parkinson’s care, the question is shifting from “Can it help?” to “How do we use it well?”
The tools are already here, some in clinics, others still in development, but their real impact depends on thoughtful integration. That means designing systems that work for clinicians, not just engineers. It means building models that reflect the diversity of real patients, not just ideal datasets. And it means making sure that patients remain at the center of every AI-enabled decision.
This is no longer about futuristic medicine. It’s about making today’s care more informed, more consistent, and better equipped to keep up with the complexity of Parkinson’s disease.
Want to Learn More?
If you’re interested in how AI is being used across neurology, here are a few topics worth exploring:
References and Further Reading
- Twala, B. (2025). AI-driven precision diagnosis and treatment in Parkinson’s disease: A comprehensive review and experimental analysis. Frontiers in Aging Neuroscience, 17, 1638340. DOI: 10.3389/fnagi.2025.1638340, https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2025.1638340/full
- Valerio, J. E., Aguirre Vera, G. D., Fernandez Gomez, M. P., Zumaeta, J., & M., A. (2025). AI-Driven Advances in Parkinson’s Disease Neurosurgery: Enhancing Patient Selection, Trial Efficiency, and Therapeutic Outcomes. Brain Sciences, 15(5), 494. DOI: 10.3390/brainsci15050494, https://www.mdpi.com/2076-3425/15/5/494
- Boutet, A. et al. (2021). Predicting optimal deep brain stimulation parameters for Parkinson’s disease using functional MRI and machine learning. Nature Communications, 12(1), 3043. DOI: 10.1038/s41467-021-23311-9, https://www.nature.com/articles/s41467-021-23311-9
- Patwekar, M., Patwekar, F., Sanaullah, S., Shaikh, D., Almas, U., & Sharma, R. (2023). Harnessing artificial intelligence for enhanced Parkinson’s disease management: Pathways, treatment, and prospects. Trends in Immunotherapy, 7(2). DOI: 10.24294/ti.v7.i2.2395, https://ojs.ukscip.com/index.php/ti/article/view/463
Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.